Collgard Biopharmaceuticals Overview
- Year Founded
-
1996
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1M
Collgard Biopharmaceuticals General Information
Description
Developer of tissue therapeutics. The company develops unique therapeutic products that affect the turnover of collagen to prevent or treat scleroderma, solid tumors, restenosis and other fibrotic disorders.
Contact Information
Corporate Office
- 15 Gonen Street
- Kiryat Matalon
- Petach Tikva
- Israel
Corporate Office
- 15 Gonen Street
- Kiryat Matalon
- Petach Tikva
- Israel
Collgard Biopharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 01-Mar-2011 | $1M | Completed | Product Development | ||
| 2. Early Stage VC | Completed | |||||
| 1. Early Stage VC (Series A) | $7M | $7M | Completed |
Collgard Biopharmaceuticals Patents
Collgard Biopharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20080255165-A1 | Having the (2''r,3''s)trans configuration and being essentially free of the (2''s,3''r)trans enantiomer and 3 position of piperidine ring substituted with hydroxy, acetoxy or lower alkoxy; disorders associated with fibrotic conditions or cell proliferation; side effect reduction | Inactive | 23-Feb-2005 | ||
| AU-2006217453-A1 | Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone | Inactive | 23-Feb-2005 | ||
| CA-2600046-A1 | Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone | Inactive | 23-Feb-2005 | ||
| EP-1855684-A2 | Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone | Inactive | 23-Feb-2005 | ||
| EP-1855684-A4 | Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone | Inactive | 23-Feb-2005 | A61K31/517 |
Collgard Biopharmaceuticals Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Denali Ventures | Venture Capital | Minority | ||
| Medica Venture Partners | Venture Capital | Minority |
Collgard Biopharmaceuticals FAQs
-
When was Collgard Biopharmaceuticals founded?
Collgard Biopharmaceuticals was founded in 1996.
-
Where is Collgard Biopharmaceuticals headquartered?
Collgard Biopharmaceuticals is headquartered in Petach Tikva, Israel.
-
What industry is Collgard Biopharmaceuticals in?
Collgard Biopharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Collgard Biopharmaceuticals a private or public company?
Collgard Biopharmaceuticals is a Private company.
-
What is the current valuation of Collgard Biopharmaceuticals?
The current valuation of Collgard Biopharmaceuticals is .
-
What is Collgard Biopharmaceuticals’s current revenue?
The current revenue for Collgard Biopharmaceuticals is .
-
How much funding has Collgard Biopharmaceuticals raised over time?
Collgard Biopharmaceuticals has raised $20M.
-
Who are Collgard Biopharmaceuticals’s investors?
Denali Ventures and Medica Venture Partners have invested in Collgard Biopharmaceuticals.
-
When was Collgard Biopharmaceuticals acquired?
Collgard Biopharmaceuticals was acquired on 01-Mar-2011.
-
Who acquired Collgard Biopharmaceuticals?
Collgard Biopharmaceuticals was acquired by Akashi Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process